Purpose of review The aim is to assess the evidence in support of home-based versus clinic-based screening for sexually transmitted infections.
Introduction
In the United States, chlamydial and gonorrheal infections are a major public health concern as they remain the most common reportable infectious diseases in the country. More than 1.5 million cases of chlamydia and gonorrhea were reported to the Centers for Disease Control and Prevention in 2008 [1] . Screening for sexually transmitted infections (STIs) is particularly important as most infections with Chlamydia trachomatis and Neisseria gonorrhoeae are asymptomatic and remain undiagnosed or untreated [2, 3] . Major sequelae can result, including pelvic inflammatory disease (PID), tubal infertility, ectopic pregnancy, and chronic pelvic pain in women, and epididymitis in men [4] [5] [6] .
Home-based screening strategies using self-collected, mail-in specimens are a feasible approach to screen for STIs, and have been implemented in many populationlevel screening studies in Sweden [7] , Denmark [8] , the UK [9, 10] , and the Netherlands [11, 12] . Additional evidence suggests that home-based STI tests may be even more acceptable and effective than traditional STI testing at a clinic [8, 13] . This review examines the published literature from January 2007 to August 2010 for studies comparing home-based with clinic-based screening for STIs.
Randomized controlled trials
We identified a total of seven randomized controlled trials (RCTs) comparing home-based vs. clinic-based STI screening (Table 1) [14 ,15,16,17 ,18,19 ,20 ] . The literature review included a PubMed/MEDLINE search of the literature from January 2007 to August 2010 (MeSH terms: sexually transmitted diseases; Chlamydia trachomatis; chlamydia infections; Neisseria gonorrhoeae; mass screening; home care services; self care; self-examination; postal service; specimen handling; and reagent kits, diagnostic) and review of bibliographies of key articles in the medical literature. Of the seven RCTs, three were conducted in the United States [14 ,17 ,18] and two were conducted in lower income populations in South Africa and Brazil [19 ,20 ] ; the remaining two studies focused primarily on home-based methods for contact tracing as opposed to STI screening [15, 16] , and therefore are not discussed in this review. Notably, we found seven additional RCTs outside of the review To determine whether more women will screen for GC, CT, and TV when offered home-based vs. clinic-based screening in a low-income setting. By 6-week follow-up visit, 93% of home-testers completed screening compared to 89% of clinictesters (RR 1.04, 95% CI 1.00-1.09). Majority of home participants preferred self-collection at home (61%). Home-testers required to drop off specimens at the study clinic rather than mail them.
(continued overleaf ) period, including two large trials conducted in Denmark [8, 13] , a study in Scotland [25] , a study examining STI rescreening [26] , as well as two RCTs centered on partner management and contact tracing [27, 28] , and an RCT follow-up study that examined the incidence of PID 1 year following either home-based or clinic-based STI screening [29] .
Studies conducted in the United States
The most recent RCT comparing home-based with clinic-based STI screening was conducted by Graseck et al. [14 ] in St. Louis, Missouri. The results of this trial were an extension of their findings in an earlier observational study, described in further detail later in this review [21 ] . In this RCT, 558 women using long-acting reversible contraception (LARC) were randomized to STI screening at home or at a clinic, either with their regular healthcare providers or at one of four family planning clinics. A total of 243 women (44.3%) completed STI screening. However, women were more likely to complete screening when they were randomized to receive a home test kit (56.3%) than when they were invited to screen at a clinic [32.9%, relative risk (RR) 1.7, 95% confidence interval (CI) 1.4-2.0]. Furthermore, of 122 women who completed a survey regarding testing satisfaction, all women reported use of the vaginal selfswab to be easy, and 70% felt self-collection of vaginal samples was extremely easy. The majority of hometesters (83%) also preferred home STI testing in the future, whereas only 49% of clinic-testers preferred to be tested at a clinic (P < 0.001). These results suggest that, compared with traditional screening at a clinic, home-based STI screening is a more effective and favored screening approach among women. Home screening may encourage more women to complete testing, particularly for LARC method users who may be less likely to visit a clinic compared with those using other contraceptive methods.
In Seattle, Washington, a population-based, randomized STI screening trial was conducted to compare the effectiveness of three different outreach methods to improve the rates of chlamydia screening in men [17 ] . Between November 2001 and October 2002, 8820 men, ages 21-25 years, from a managed care plan were randomized to one of three different screening strategies: an invitation letter offering C. trachomatis screening in addition to a card that could be mailed back to request a home test kit; an invitation letter in addition to direct mailing of a home test kit; or usual clinical care (control group) in which STI testing was provided only if the participant presented to one of the managed care clinics. A reminder letter was sent to the men in the two intervention arms after 3-4 weeks had elapsed. At 4 months postrandomization, significantly more men completed C. trachomatis testing when they were sent an invitation letter in addition to either a test-request card (3.6%, RR 5.6, 95% CI 3.6-7.8) or direct mailing of a home test kit (7.8%, RR 11.1, 95% CI 7.3-16.9) compared with usual clinical care (0.8%). However, more men completed C. trachomatis testing when they received a home test kit directly than when they were asked to mail back a test-request card (RR 2.3, 95% CI 1.8-2.9). Although these results suggest that home-based STI screening is more effective than clinic-based screening, these findings are limited by the fact that the intervention groups received screening invitations and reminder letters, whereas the control group received neither. In effect, the intervention group received cointerventions that may have encouraged men to complete STI testing beyond that of a home test kit or test-request card alone.
In the Detection Acceptability Intervention for STDs in Young Women (DAISY) study, home-based STI screening similarly outperformed clinic-based screening [18] . Four hundred and three women, ages 15-24 years, with recent STIs or risk factors for STIs were recruited from clinics and surrounding neighborhoods and randomized to receive repeated STI screening at 6, 12, and 18 months postenrollment either at a clinic or at home. Postcards were sent to the clinic group at 6, 12, and 18 months inviting the women to attend STI screening at the clinic, whereas home test kits were picked up by or directly mailed to the home testing group at 6, 12, and 18 months. By the end of the study, women in the home testing group completed more overall tests than those in the clinic group (RR 1.38, 95% CI 1.23-1.55), and they completed more tests when they were asymptomatic (RR 1.57, 95% CI 1.34-1.83). The investigators concluded that home STI screening is a feasible approach to improve STI screening rates in high-risk young women, particularly those with less regular attendance at healthcare clinics.
Studies conducted in low-income and resource-poor communities
Two similar trials were conducted concurrently in South Africa and Brazil comparing home-based with clinicbased screening for N. gonorrhoeae, C. trachomatis, and Trichomonas vaginalis [19 ,20 ] . In Gugulethu, South Africa, Jones et al. [19 ] randomized 626 women to self-collection using a test kit at a clinic under supervision of a nurse, or using an identical test kit at home to be mailed back to study staff. Women in the home testing group (60%) were more likely to self-collect a vaginal sample than women in the clinic testing group (42%, RR 1.4, 95% CI 1.2-1.7), and a majority of women in both the home and clinic testing groups said self-collection was easy/very easy. However, compared with home-testers, more clinic-testers reported self-collection to be easy/ very easy (96.2 vs. 85.5%, RR 1.12, 95% CI 1.03-1.22). Among home-testers, self-collection at home was acceptable and preferred by a majority of women (58%), whereas most clinic-testers (66%) preferred self-collection at the clinic. These findings indicate that self-collection of vaginal specimens for STI screening is a feasible practice in both clinic and home settings. Making home test kits easily available may be particularly valuable in this setting as 22% of women in the study population tested positive for C. trachomatis, 10% for T. vaginalis, and 8% for N. gonorrhoeae.
A randomized trial with similar methodology was conducted by Lippman et al. [20 ] in São Paulo, Brazil, in which 818 low-income women were randomized to selfcollect vaginal specimens with STI test kits either at a clinic or at home. However, in this study, participants were required to drop off their completed test kits at the clinic instead of mailing it to study staff, eliminating much of the benefit of home STI testing. The testing rate was nevertheless slightly higher among home-testers (93%) compared with clinic-testers (89%) at their 6-week follow-up visit (RR 1.04, 95% CI 1.00-1.09). Similar to the findings of Jones et al., a majority of home-testers (61%) preferred self-collection at home; however, only 26% of clinic-testers preferred home-based testing in the future. The randomization group most strongly predicted a woman's testing preference. In this setting as well, offering home test kits appears to be feasible as 96% of all participants said self-collection of vaginal samples was easy, and that they felt comfortable doing so.
Observational studies
Our PubMed/MEDLINE search returned two relevant controlled, observational studies within the study period that compared home-based with clinic-based STI screening (Table 1 ) [21 ,22] . As mentioned previously, Graseck et al. [21 ] conducted an observational study as a prelude to their RCT. Their observational study examined the selection and STI testing rates of 462 women who were offered the option of STI testing at home or at a clinic. A majority of women (75.5%) chose home-based STI testing, whereas only 16.1 and 8.2% chose to be tested at a family planning clinic or with their own providers, respectively; all comparisons were significantly different from one another (P < 0.001). Overall, 56.6% of women completed STI testing, but home-testers were more likely to complete testing than clinic-testers (64.6 vs. 31.6%, RR 2.04, 95% CI 1.51-2.76). The investigators' findings indicate high acceptability of home-based STI screening among women and suggest that home-based approaches may be more effective in improving STI screening rates than testing in traditional clinic venues.
Another study in Scotland compared different outreach strategies for chlamydia screening in venues outside of genitourinary medicine clinics [22] . Williamson et al. [22] offered home test kits at commercial settings (e.g. record stores and pharmacies), a sexual health clinic, and local colleges, as well as clinic-based testing conducted by nurses at the sexual health clinic or on college campuses. A total of 4475 young individuals (15.2% men, 84.8% women), ages 13-25 years, completed testing; 51.3% completed home test kits, 42.0% tested at the clinic, and 6.7% tested on college campuses. A majority of men (80.2%) used home test kits, whereas only 46.1% of women were home-testers and 48.1% were clinic-testers. The C. trachomatis incidence was 12.3% among men and 10.6% among women. These findings indicate that distributing home test kits at commercial venues is a feasible approach and suggest that home testing may be a particularly good option to increase STI screening rates in men.
Economic and cost analyses
We identified two studies from our PubMed/MEDLINE search that discussed the costs and cost effectiveness of home-based STI screening (Table 1 ) [23, 24] . In the UK, Roberts et al. [23] used a transmission dynamic model to compare the cost effectiveness of population-based STI screening using home test kits compared with a policy of nonorganized screening (i.e. mostly opportunistic screening in which individuals are screened for STIs during clinic visits for other reasons). The investigators concluded that home-based screening was not cost effective. However, we noted several limitations to this report. The study's primary objective was to evaluate a systematic, population-level STI screening program in the UK compared with opportunistic screening; it is not a direct assessment of home-based vs. clinic-based STI screening. In addition, the investigators did not include chronic pelvic pain as a fairly common and costly adverse outcome of PID. Thus, this study will not be discussed in further detail in this review.
In the United States, Smith et al. [24] compared the costs associated with STI screening at home vs. at a clinic using data gathered from the DAISY study described previously [18] . Clinic testing was calculated to cost $111 per test, including $49 in direct costs and $62 in indirect costs such as transportation, childcare, and missed work (2005 prices). In comparison, home testing was calculated to cost $25 per test, which was determined to be cost saving for the overall study population. When only participants recruited from clinics were considered, a group with higher baseline clinic utilization rates, home testing was also found to be cost saving because the availability of home test kits allowed this subset of women to reduce their use of clinic services. However, when considering only the subset of women recruited from surrounding neighborhoods, home testing was not considered cost saving because the increase in home testing was not accompanied by a corresponding reduction in clinic testing. This result does, however, suggest that home screening may tap at-risk populations that might normally have less access or inclination to utilize clinic services for STI screening, which may prove to be cost saving from a public health perspective.
Strengths and limitations
Recent studies comparing home-based with clinic-based STI screening include both men and women from a wide range of social and economic settings, and several are conducted as RCTs, providing stronger evidence that home test kits can be used effectively to test for STIs. However, these studies are also limited because of important differences in methodology. For instance, participants in some studies may have been more encouraged to complete home testing because of study elements like reminder letters. On the other hand, participants in other studies may have been less encouraged to complete home testing because they were required to hand-deliver their test kits to the study clinic. Cost-effectiveness studies are also limited because they do not account for all of the direct and indirect costs associated with STI complications and treatment, and they are based on different estimates of screening uptake and STI complication rates.
Conclusion
The recent evidence indicates that home-based STI screening is a feasible, well-accepted, and often preferred approach to test for STIs compared with testing at a traditional clinic venue. In almost all studies, higher testing rates were achieved with home-based compared with clinic-based STI screening in both men and women. This suggests that the availability of home-based testing may improve STI screening rates among young, high-risk individuals, particularly those with less clinic access. Future cost-effectiveness analyses comparing homebased with clinic-based STI screening should incorporate population-specific estimates of screening rates, STI prevalence, and incidence of all adverse STI outcomes.
